Edit
Constellation Pharmaceuticals
http://www.constellationpharma.com/Last activity: 06.11.2022
Active
Developing novel medicines through scientific innovation to better patients' lives.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Phone: +1 617-577-0470
Total raised: $142M
Founded date: 2008
Investors 5
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| 06.11.2022 | Hercules C... | htgc.com |
| - | The Column... | thecolumng... |
| - | Timefolio ... | timefolioc... |
| - | Bain Capit... | baincapita... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 10.04.2018 | - | $100M | - |
| 06.08.2014 | - | $5M | - |
| 06.06.2011 | Series B | $15M | - |
| 02.06.2010 | Series B | $22M | - |
Mentions in press and media 19
| Date | Title | Description |
| 04.06.2021 | CONSTELLATION PHARMACEUTICALS, INC. Constellation Pharmaceuticals : Corporate Presentation—June 4, 2021 | Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the Com... |
| 03.06.2021 | Salesforce wants to battle Microsoft. But will it get Slack right? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Late last year, Salesforce threw down a weighty gauntlet to Microsoft’s work-from-home Teams soft... |
| 03.06.2021 | CONSTELLATION PHARMACEUTICALS, INC. Constellation Pharmaceuticals : MorphoSys to Acquire Constellation Pharmaceuticals (Form 8-K) | MorphoSys to Acquire Constellation Pharmaceuticals Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Be... |
| 02.06.2021 | MORPHOSYS AG MorphoSys : to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma | DGAP-Ad-hoc: MorphoSys AG / Key word(s): Mergers & Acquisitions MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma 02-Jun-2021 / 13:22 CET/CEST Disclosure of an inside ... |
| 02.06.2021 | MORPHOSYS AG MorphoSys : to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma | Ad hoc release according to article 17 para. 1 MAR Planegg/Munich, Germany and Cambridge, Mass., June 2, 2021 Ad hoc: MorphoSys to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma Morpho... |
| 02.06.2021 | MORPHOSYS AG MorphoSys : to Acquire Constellation Pharmaceuticals | DGAP-News: MorphoSys AG / Key word(s): Mergers & Acquisitions MorphoSys to Acquire Constellation Pharmaceuticals 02.06.2021 / 13:24 The issuer is solely responsible for the content of this announcement. MorphoSys to Acquire Constellatio... |
| 07.12.2020 | Updated: #ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $2.75B buyout | UniQure may be getting all the ASH attention for hemophilia B, but Pfizer is trying to carve out a niche in hemophilia A. The pharma giant and its gene editing partner Sangamo announced long-term data from their Phase I/II... |
| 06.12.2020 | Constellation’s blood cancer drug shows greater benefit, easing concerns about its future | More patients and an improved response rate might once again shift the sentiment on Constellation Pharmaceuticals and its contentious drug for myelofibrosis — this time in a positive direction. With 63 myelofibrosis patients now treated and... |
| 10.04.2018 | Constellation Pharmaceuticals Raises $100M Financing | Constellation Pharmaceuticals, Inc., a Cambridge, MA-based clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its research and development in cancer epigenetics, raised $100m in financi... |
| 09.04.2018 | Term Sheet — Monday, April 9 | BIG PLAYS Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop BOMBSHELL DEAL: This morning, Novartis CEO Vasant Narasimhan announced the company would buy gene-therapy developer AveX... |
Show more